Clementia Pharma Enters the Market With a Bang
Clementia Pharmaceuticals entered the market with a bang, with shares priced above expected price range.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 162
Why Pfizer Earnings Aren’t Exciting Investors
Pharmaceuticals maker Pfizer reported second-quarter earnings before markets opened Tuesday, beating profit estimates by a penny a share, but coming up short on revenues.
Over 90 Million Americans Used Prescription Opioids in 2015
No wonder there is a national problem with opioid use. A contributing factor has to be that almost 92 Americans used opioids in 2015.
AbbVie Slips Despite Q2 Earnings Beat
AbbVie reported better-than-expected second-quarter financial results before the markets opened on Friday.
Tetraphase Pharma Decides to Reap Profits With Secondary Offering
Tetraphase Pharmaceuticals saw its shares pull back on Friday after the company announced that it has priced a secondary offering.
Analyst Has Top Biotech Stocks to Buy as Sector Stays Red Hot
After a wretched 2016, when many of the top biotech companies were hit hard by campaign rhetoric, the industry has roared back to life this year. Here are four big opportunities for aggressive investors.
Report Claims Pittsburgh Officials Misled Public Over Tainted Water
Residents in Pittsburgh were given "misleading" statements by health officials who "deflected" attention from lead-contaminated water, according to a recent report.
Short Sellers Run for Cover From Major Biotech Stocks
The July 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Major Pharma Short Interest Takes a Big Step Back
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Clementia Pharmaceuticals Announces Potential Pricing for IPO
Clementia Pharmaceuticals intends to price more than 7 million shares in a range that will result in an initial public offering valued up to more than $123 million.
Reata Pharma Greenlights Phase 3 in Chronic Kidney Disease Trial
Reata Pharmaceuticals saw its shares make an incredible gain to kick off the week after it reported initial data from its mid-stage trial evaluating bardoxolone in patients with chronic kidney disease.
Why Credit Suisse Prefers Johnson & Johnson Over Pfizer
Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the pack with Eli Lilly and Co. (NYSE: LLY) in a close second. However, one…
Vertex Wins Big in Mid-Stage Cystic Fibrosis Trial
Shares of Vertex Pharmaceuticals shot up after the company announced dramatic results from its early and mid-stage trials in cystic fibrosis. The stock pushed to an all-time high on the back of these results.
SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017
A new report from SunTrust Robinson Humphrey indicates big pharmaceuticals may be the place to be for investors. Among the report's top picks: AbbVie, Eli Lilly, Merck, and Shire.
Gilead Secures FDA Approval For Chronic Hepatitis C Re-Treatment
Gilead Sciences, Inc. (NASDAQ: GILD) shares basically remained unchanged after the firm announced an approval from the U.S. Food and Drug Administration (FDA). Essentially, the FDA approved Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100…